Peptide questions · Tirzepatide
Tirzepatide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for tirzepatide are nausea, diarrhea and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: Across the SURMOUNT program and the FDA Zepbound label, the dominant adverse events are gastrointestinal (nausea, diarrhea, vomiting, constipation), mostly mild-moderate and escalation-related.
What is commonly reported with tirzepatide
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Fatigue
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Retatrutide, Liraglutide and 17 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Retatrutide, Liraglutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Retatrutide, Liraglutide and 14 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Retatrutide, Liraglutide and 9 more |
| Abdominal pain | 7: Semaglutide (oral), Retatrutide, Dulaglutide, Setmelanotide and 3 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Retatrutide, Dulaglutide and 5 more |
| Fatigue | 7: Semaglutide, Retatrutide, Dulaglutide, Survodutide and 3 more |

Model. Individual results vary.
Which tirzepatide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on tirzepatide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is tirzepatide’s own.
What the tirzepatide safety notes say
The library’s safety note
Across the SURMOUNT program and the FDA Zepbound label, the dominant adverse events are gastrointestinal (nausea, diarrhea, vomiting, constipation), mostly mild-moderate and escalation-related. The label carries a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance undetermined; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2). Trial-adjudicated acute pancreatitis was ~0.2% (similar to placebo); gallstones were ~1.1% vs 1.0% on placebo and gallbladder inflammation 0.7% vs 0.2%, partly attributable to rapid weight loss. These are trial/label findings to review with your clinician.
The library’s interaction note
Tirzepatide delays gastric emptying and can reduce the absorption of concomitant oral medications — the label specifically flags reduced oral-contraceptive efficacy, a documented interaction to discuss with a clinician. Co-use with insulin or insulin secretagogues (sulfonylureas) increases hypoglycemia risk per the label, warranting clinician-guided dose review and glucose monitoring. No specific documented interaction with SSRIs, anticoagulants, or thyroid replacement beyond general caution; raise all medications with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the tirzepatide reports come from
The library rates the evidence on tirzepatide as established: clinical trials or FDA-approved use exist.
Of the library’s 9 research notes on tirzepatide, 7 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 19 study pages on tirzepatide: 18 randomized trials and 1 animal study (mice).
So tirzepatide has controlled trials in people to set its listed effects against.
What our tirzepatide study pages report on safety
Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE
Randomized trial, human, 2026: Side effects were about as common in both groups: 39 of 51 (76%) on apitegromab and 36 of 51 (71%) on placebo, and serious side effects occurred in 1 of 51 people in each group.
Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks
Randomized trial, human, 2026: The most common side effects with tirzepatide were stomach and gut problems, mostly mild to moderate and mostly during dose increases. Keeping tirzepatide at the full tolerated dose held weight off best over a further year, a lower 5 mg dose kept much of the loss, and switching to placebo led to regain in many people.
Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1
Randomized trial, human, 2025: Apart from COVID-19, the most common side effects were gastrointestinal, mostly mild to moderate and mainly in the first 20 weeks while doses were being raised, and the trial found no new safety signals.
Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks
Randomized trial, human, 2025: In both groups the most common side effects were gut-related, mostly mild to moderate, and they came mainly while doses were being raised. In a direct head-to-head trial, tirzepatide led to more weight and waist loss than semaglutide over 72 weeks, and gut-related side effects were the most common in both groups.
Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CN
Randomized trial, human, 2024: Stomach and gut side effects were the most common with tirzepatide, mostly mild to moderate, and fewer than 5% of events led people to stop treatment. In Chinese adults without diabetes, both the 10 mg and 15 mg arms of tirzepatide led to far more weight loss than placebo over a year, with gut side effects the most common problem.
Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSA
Randomized trial, human, 2024: For people with obesity and moderate-to-severe sleep apnea, this pair of trials found tirzepatide cut breathing events during sleep well beyond placebo, whether or not they used a PAP machine, with mostly mild to moderate stomach-related side effects.
Questions people ask
What are the side effects of tirzepatide?
The side effects most commonly reported for tirzepatide are nausea, diarrhea and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do tirzepatide’s side effects come from human studies?
The library rates the evidence on tirzepatide as established, and the library’s evidence on it includes controlled trials in people.
Which tirzepatide side effects are its own?
None: each effect the library lists for tirzepatide is listed for at least one other metabolic & GLP-1 compound too.
Does tirzepatide interact with other medicines?
The library’s interaction note on tirzepatide begins: tirzepatide delays gastric emptying and can reduce the absorption of concomitant oral medications — the label specifically flags reduced oral-contraceptive efficacy, a documented interaction to discuss with a clinician.